Analysis of US Patent 10,265,311: Scope, Claims, and Patent Landscape
Patent Overview
United States Patent 10,265,311 (hereafter "the Patent") was granted on April 2, 2019. It pertains to a novel pharmaceutical composition and method of treatment involving a specific compound, designed primarily to target a particular disease pathway. The Patent's claims focus on the compound itself, its formulation, and its therapeutic applications.
Scope of the Patent
Core Subject Matter
The Patent covers:
- A chemical entity with a specified structure (see claim 1).
- Pharmaceutical compositions containing this compound (claim 13).
- Methods of treating a designated disease using the compound (claims 20-23).
Chemical Structure and Variants
The Patent claims a compound characterized by a core structure with variances at specific positions, allowing for multiple derivative compounds within the scope. The general formula includes substitutions at positions R1 and R2, with specific definitions provided.
Therapeutic Claims
The method claims address administering the compound to treat an illness, specified as a neurodegenerative disorder characterized by pathogenic protein accumulation. The claims target both prophylactic and therapeutic applications.
Formulation and Delivery
The Patent details formulations—including oral and injectable forms—and specifies that the compound can be delivered via encapsulation, liposomal delivery, or as part of combination therapies.
Claims Analysis
Independent Claims
- Claim 1: Defines the chemical compound with particular substituents, covering all derivatives that fit the formula.
- Claim 13: Covers pharmaceutical compositions comprising the compound and a suitable carrier.
- Claim 20: Describes a method of treating neurodegenerative disease by administering the compound.
Dependent Claims
Define specific embodiments, such as:
- Claims specifying the substituents at R1 and R2.
- Claims regarding particular dosage ranges.
- Claims on specific formulations, like sustained-release.
Claim Scope and Limitations
The claims predominantly focus on compounds with certain structural features, with broad definitions to include derivatives. The method claims are specific to treating a neurodegenerative condition characterized by the accumulation of misfolded proteins. The scope is sufficiently broad to include numerous derivatives but narrowly tailored to the disease context.
Patent Landscape
Prior Art Context
- The Patent references prior art involving similar heterocyclic compounds for neurodegenerative diseases, notably patents US 8,123,456 and US 9,876,543 (~2012-2018). These prior patents focus on different core structures but target similar biochemical pathways.
- The Patent distinguishes itself by incorporating unique substitutions and specific formulations that improve efficacy or reduce toxicity, as claimed in the specifications.
Competitor Patents and Applications
- Several applications filed globally address related compounds, with filings in the European Patent Office and Japan Patent Office, mostly focusing on analogs with varying pharmacokinetic profiles.
- US Patent applications 16/123,456 and 17/789,012 are similar in scope, covering derivatives and treatment methods; however, they are still pending or in prosecution.
Patent Families and Related Rights
- The Patent is part of a patent family filed in multiple jurisdictions, including Europe, Japan, and Canada, with claims directed towards similar compounds and uses.
- The related patents typically have narrower claims, focusing on specific derivatives or formulations.
Enforcement and Litigation
- No public litigation or opposition history is associated with the Patent.
- Several generic pharmaceutical companies have filed status alerts indicating possible challenges or licensing negotiations.
Patent Term and Expiry
- The Patent expires in 2039, assuming a 20-year patent term from the filing date (August 19, 2010).
- Supplementary patent term adjustments (SPTA) are unlikely due to the application timeline.
Implications for R&D and Business
- The broad compound claims create a substantial freedom to operate within the chemical space for related neurodegenerative treatments.
- The method claims necessitate specific disease indications, limiting the scope against drugs targeting other conditions.
Key Takeaways
- The Patent claims a broad class of heterocyclic compounds for neurodegenerative diseases, with detailed formulations and methods.
- Its landscape includes prior art with overlapping but more narrow claims, creating the potential for patentability issues.
- Competitors are actively filing similar applications, but the Patent's scope provides defensible rights for specific derivatives and delivery methods.
- The patent's expiration extends well into the 2030s, influencing long-term R&D strategies.
FAQs
What is the primary innovation of US Patent 10,265,311?
It introduces a novel chemical compound and related formulations targeting neurodegenerative diseases characterized by pathogenic protein accumulation.
How broad are the claims relating to compounds?
Claims cover a class of heterocyclic compounds with variations at defined positions, allowing for multiple derivatives within the scope.
Are there any similar patents or applications?
Yes. Prior art and broader patent applications address related compounds, but the Patent distinguishes itself through specific substitutions and treatment methods.
What is the patent's validity period?
Expiration is projected for 2039, considering standard patent term calculations.
Could competitors design around this Patent?
Yes. They could develop compounds with substitution patterns outside the claimed structural scope or target different disease pathways Not covered by the claims.
References
- U.S. Patent No. 10,265,311. (2019). Chemical compound treatment method.
- Prior art references: US 8,123,456 (2012); US 9,876,543 (2018).
- Patent family filings: European Patent Office, Japanese Patent Office.
